CSL achieves a global milestone as Japan approves ARCT-154, the first sa-mRNA COVID-19 vaccine, showcasing CSL's commitment to innovation, efficacy, and prolonged protection against variants. Jonathan Edelman, MD, senior VP of CSL Vaccine’s Innovation Unit, speaks with ICT.
A patient receiving a COVID-19 vaccine.
(Adobe Stock 639765475 by Talia Mdlungu/peopleimages.com)
Despite the appearance of the public emergency waning, the battle against COVID-19 persists. An integral aspect of this ongoing struggle involves the tireless global pursuit of novel vaccines. The quest for innovative and effective vaccine candidates remains crucial in fortifying our defenses against the virus, adapting to emerging variants, and achieving comprehensive immunity in the face of the pandemic’s evolving challenges. This commitment to exploring new vaccine possibilities underscores the collective determination to safeguard communities worldwide and mitigate the long-term impact of the COVID-19 threat.
Answering questions from Infection Control Today® (ICT®) about the groundbreaking approval of ARCT-154, the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine by Japan's Ministry of Health, Jonathan Edelman, MD, Senior VP of CSL's Vaccines Innovation Unit, discusses this historic milestone. Edelman elaborates on the vaccine's significance, clinical findings, collaboration with Meiji Seika Pharma, and how sa-mRNA technology addresses challenges, ushering in a new era for vaccine platforms.
ICT: Can you elaborate on the significance of Japan's Ministry of Health, Labour and Welfare granting approval for ARCT-154, the self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, and how it reflects CSL's commitment to global public health?
Jonathan Edelman, MD: This approval in Japan is a historic milestone for CSL, as it marks the world’s first self-amplifying mRNA vaccine approved for COVID-19 in adults. The milestone underscores CSL’s promise to develop and deliver innovations where there is a public health need. The approval also expands CSL’s comprehensive portfolio of innovative vaccines that combat respiratory viral diseases and is the first sa-mRNA vaccine.
ICT: With ARCT-154 being the first sa-mRNA vaccine in the world to be registered, how does this milestone contribute to the evolution of mRNA vaccine technology and its potential impact on protecting against COVID-19 and other infectious diseases?
JE: We believe the technology behind our novel, self-amplifying messenger RNA vaccine, ARCT-154, has the potential to create more potent cellular immune responses with increased duration of protection, all with lower doses of mRNA.
ICT: The approval is based on positive clinical data, including studies conducted in Vietnam and a Phase 3 COVID-19 booster trial. Could you share key findings from these studies and how they demonstrate the efficacy and safety profile of ARCT-154 compared to standard mRNA COVID-19 vaccines?
JE: The efficacy of ARCT-154 was established in a Phase 1,2,3 study conducted in Vietnam during the height of the Delta wave of the pandemic, showing 95% protection against severe disease, including death, and 55% protection against all infections, published on MedRxiv and under peer review currently.
The Phase 3 booster study published in The Lancet Infectious Diseases found that ARCT-154 produced a higher (noninferior) immune response after 4 weeks against the original Wuhan-Hu-1 virus and, importantly, a superior immune response against the Omicron BA4/5 variant of COVID-19 compared to the standard mRNA vaccine Comirnaty. [This was a double-blind, multicenter, randomized, controlled, phase 3, non-inferiority trial.]
ICT: CSL Seqirus partnered exclusively with Meiji Seika Pharma to distribute ARCT-154 in Japan. How does this collaboration strengthen CSL's position in providing innovative vaccines for respiratory viral diseases, especially in the ongoing global efforts to combat COVID-19?
JE: Collaborating with Meiji Seika Pharma provides a partner with the infrastructure in Japan to market and distribute our self-amplifying mRNA COVID-19 vaccine and will mark CSL’s entry into the COVID-19 vaccine market with differentiated, self-amplifying mRNA technology.
ICT: The sa-mRNA technology used in ARCT-154 can potentially create more potent cellular immune responses and increase the duration of protection. Could you discuss how this innovation addresses key challenges in vaccine development and administration and what implications it may have for future vaccine platforms and strategies?
JE: One challenge with the original mRNA vaccines for COVID-19 is that their protection seems to wane within 6 months of administration, requiring frequent revaccination. A second challenge is that they have limited ability to protect against emerging variants until the vaccine is updated to that new variant. We believe sa-mRNA technology found in ARCT-154 can address both of these limitations by providing protection that lasts up to 1 year from vaccination and offering a broader range of coverage for variants of concern as evidenced by the Japan booster study and other data presented at the recent mRNA meeting in Berlin last year.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.